Choksi Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 6:55 pm

Quick Insight

Choksi Laboratories Ltd, a player in the Medical Research Services industry, currently trades at ₹185 with a market cap of ₹129 Cr. The company's high P/E ratio of 84.6 reflects market expectations for future growth, despite a modest ROE of 6.63% and ROCE of 9.13%. With an OPM of 30.70%, Choksi Laboratories demonstrates strong operational efficiency, though its net profit stands at 1.52 Cr. The company's debt level, with borrowings of ₹28.42 Cr against reserves of 16.64 Cr, warrants attention. Moreover, the high P/BV ratio of 3.55x and comfortable ICR of 4.27x indicate investor optimism but also potential risks. In conclusion, investors should closely monitor Choksi Laboratories' ability to leverage its operational efficiency to drive bottom-line growth while keeping an eye on its debt management strategies to ensure sustainable financial health.

Competitors of Choksi Laboratories Ltd

All Competitor Stocks of Choksi Laboratories Ltd

Quarterly Result

Last Updated: July 16, 2025, 10:25 am

Below is a detailed analysis of the quarterly data for Choksi Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 11.40 Cr.. The value appears strong and on an upward trend. It has increased from 10.38 Cr. (Dec 2024) to 11.40 Cr., marking an increase of 1.02 Cr..
• For Expenses, as of Mar 2025, the value is 7.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.84 Cr. (Dec 2024) to 7.90 Cr., marking an increase of 0.06 Cr..
• For Operating Profit, as of Mar 2025, the value is 3.50 Cr.. The value appears strong and on an upward trend. It has increased from 2.54 Cr. (Dec 2024) to 3.50 Cr., marking an increase of 0.96 Cr..
• For OPM %, as of Mar 2025, the value is 30.70%. The value appears strong and on an upward trend. It has increased from 24.47% (Dec 2024) to 30.70%, marking an increase of 6.23%.
• For Other Income, as of Mar 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Dec 2024) to 0.04 Cr., marking an increase of 0.03 Cr..
• For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Dec 2024) to 0.58 Cr., marking a decrease of 0.11 Cr..
• For Depreciation, as of Mar 2025, the value is 1.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.68 Cr. (Dec 2024) to 1.70 Cr., marking an increase of 0.02 Cr..
• For Profit before tax, as of Mar 2025, the value is 1.26 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Dec 2024) to 1.26 Cr., marking an increase of 1.08 Cr..
• For Tax %, as of Mar 2025, the value is 26.98%. The value appears to be improving (decreasing) as expected. It has decreased from 44.44% (Dec 2024) to 26.98%, marking a decrease of 17.46%.
• For Net Profit, as of Mar 2025, the value is 0.92 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Dec 2024) to 0.92 Cr., marking an increase of 0.81 Cr..
• For EPS in Rs, as of Mar 2025, the value is 1.32. The value appears strong and on an upward trend. It has increased from 0.16 (Dec 2024) to 1.32, marking an increase of 1.16.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:14 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:34 pm

Below is a detailed analysis of the balance sheet data for Choksi Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 6.97 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.97 Cr..
• For Reserves, as of Mar 2025, the value is 16.64 Cr.. The value appears strong and on an upward trend. It has increased from 15.25 Cr. (Mar 2024) to 16.64 Cr., marking an increase of 1.39 Cr..
• For Borrowings, as of Mar 2025, the value is 28.42 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 30.87 Cr. (Mar 2024) to 28.42 Cr., marking a decrease of 2.45 Cr..
• For Other Liabilities, as of Mar 2025, the value is 13.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.86 Cr. (Mar 2024) to 13.30 Cr., marking an increase of 4.44 Cr..
• For Total Liabilities, as of Mar 2025, the value is 65.33 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.95 Cr. (Mar 2024) to 65.33 Cr., marking an increase of 3.38 Cr..
• For Fixed Assets, as of Mar 2025, the value is 47.61 Cr.. The value appears strong and on an upward trend. It has increased from 43.43 Cr. (Mar 2024) to 47.61 Cr., marking an increase of 4.18 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.99 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 2.99 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 17.72 Cr.. The value appears strong and on an upward trend. It has increased from 15.53 Cr. (Mar 2024) to 17.72 Cr., marking an increase of 2.19 Cr..
• For Total Assets, as of Mar 2025, the value is 65.33 Cr.. The value appears strong and on an upward trend. It has increased from 61.95 Cr. (Mar 2024) to 65.33 Cr., marking an increase of 3.38 Cr..

However, the Borrowings (28.42 Cr.) are higher than the Reserves (16.64 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Choksi Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
• For Diluted EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.52. This value is within the healthy range. It has increased from 9.80 (Mar 24) to 11.52, marking an increase of 1.72.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 59.99. It has increased from 52.68 (Mar 24) to 59.99, marking an increase of 7.31.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 16.23. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 16.23, marking an increase of 1.33.
• For PBIT / Share (Rs.), as of Mar 25, the value is 6.89. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 6.89, marking an increase of 0.19.
• For PBT / Share (Rs.), as of Mar 25, the value is 3.09. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 3.09, marking an increase of 0.70.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 2.19. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
• For PBDIT Margin (%), as of Mar 25, the value is 27.04. This value is within the healthy range. It has decreased from 28.29 (Mar 24) to 27.04, marking a decrease of 1.25.
• For PBIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has decreased from 12.72 (Mar 24) to 11.49, marking a decrease of 1.23.
• For PBT Margin (%), as of Mar 25, the value is 5.15. This value is below the healthy minimum of 10. It has increased from 4.53 (Mar 24) to 5.15, marking an increase of 0.62.
• For Net Profit Margin (%), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has increased from 3.02 (Mar 24) to 3.64, marking an increase of 0.62.
• For Return on Networth / Equity (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 15. It has increased from 4.99 (Mar 24) to 6.45, marking an increase of 1.46.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 11.58, marking an increase of 0.75.
• For Return On Assets (%), as of Mar 25, the value is 2.33. This value is below the healthy minimum of 5. It has increased from 1.79 (Mar 24) to 2.33, marking an increase of 0.54.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.64, marking a decrease of 0.17.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has decreased from 1.32 (Mar 24) to 1.19, marking a decrease of 0.13.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has increased from 0.59 (Mar 24) to 0.65, marking an increase of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1.5. It has decreased from 0.77 (Mar 24) to 0.68, marking a decrease of 0.09.
• For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.66, marking a decrease of 0.09.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.73. This value is within the healthy range. It has decreased from 8.94 (Mar 24) to 6.73, marking a decrease of 2.21.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 4.27. This value is within the healthy range. It has increased from 3.45 (Mar 24) to 4.27, marking an increase of 0.82.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.37 (Mar 24) to 1.57, marking an increase of 0.20.
• For Enterprise Value (Cr.), as of Mar 25, the value is 111.15. It has increased from 58.14 (Mar 24) to 111.15, marking an increase of 53.01.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.66, marking an increase of 1.08.
• For EV / EBITDA (X), as of Mar 25, the value is 9.84. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 9.84, marking an increase of 4.24.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
• For Price / BV (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 3.55, marking an increase of 2.22.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness